WO1994028900A1 - Procedes et comositions d'abaissement de la pression intra-oculaire - Google Patents

Procedes et comositions d'abaissement de la pression intra-oculaire Download PDF

Info

Publication number
WO1994028900A1
WO1994028900A1 PCT/US1994/006278 US9406278W WO9428900A1 WO 1994028900 A1 WO1994028900 A1 WO 1994028900A1 US 9406278 W US9406278 W US 9406278W WO 9428900 A1 WO9428900 A1 WO 9428900A1
Authority
WO
WIPO (PCT)
Prior art keywords
quinine
eye
intraocular pressure
pharmaceutical composition
compound
Prior art date
Application number
PCT/US1994/006278
Other languages
English (en)
Inventor
Nino Sorgente
Charles Bakhit
Original Assignee
Vide Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/096,799 external-priority patent/US5629345A/en
Application filed by Vide Pharmaceuticals filed Critical Vide Pharmaceuticals
Priority to AU70991/94A priority Critical patent/AU7099194A/en
Priority to EP94920077A priority patent/EP0724443A4/fr
Priority to JP7501977A priority patent/JPH08511024A/ja
Publication of WO1994028900A1 publication Critical patent/WO1994028900A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates generally to compositions and methods for lowering intraocular pressure and more particularly to the administration of quinine and quinidine, and ATP-sensitive K + channel inhibitors to the eye to lower intraocular pressure for the treatment of glaucoma.
  • Glaucoma is an ocular disorder that is often manifested as an elevated intraocular pressure, i.e., pressure in the anterior chamber of the eye. It is presently believed that such elevated pressure results from inadequate transport of the intraocular fluid from the anterior chamber, resulting in a detrimental pressure increase. If left untreated, glaucoma will eventually lead to loss of vision in the affected eye.
  • topically applied drugs for the treatment of glaucoma include pilocarpine, a cholinergic; timolol maleate, a /3-adrenergic receptor blocking agent; epinephrine, an ⁇ - and ⁇ -adrenergic receptor agonist; dipivefrin, a pro drug of epinephrine; and demecarium bromide, a cholinesterase inhibitor. While these drugs are generally effective, they can have significant adverse side effects, even when administered topically.
  • Topical administration to the eye results in significant absorption leading to such undesirable systemic effects. Therefore it would be desirable to provide additional drugs useful for the treatment of glaucoma and other disorders related to elevated intraocular pressure, particularly where such drugs have fewer or reduced side effects when compared to present drugs when topically applied.
  • Such drugs should be safe, relatively non-toxic, and be amenable to incorporation in carriers and vehicles suitable for administration to the eye, either topically, by injection, or by ocular insert.
  • compositions for lowering intraocular pressure in the eye of a patient have been discovered.
  • the compositions may comprise at least one quinine compound present in a non-phosphate ophthalmically acceptable carrier in an amount effective to lower intraocular pressure when administered to an eye having elevated intraocular pressure.
  • the quinine compounds are preferably quinine, quinidine, and therapeutically equivalent salts and derivatives thereof, and are preferably present in the compositions in concentrations from about 0.1% to 5% by weight.
  • Particular formulations include those suitable for topical application, for injection, and for combination in an ocular insert.
  • the compositions may comprise at least one ATP- sensitive K + channel inhibiting compound present in an ophthalmically acceptable carrier in an amount effective to lower intraocular pressure when administered to an eye having elevated intraocular pressure.
  • the ATP-sensitive K + channel inhibiting compounds are preferably sulfonylurea compounds, more preferably being selected from the group consisting of glybenclamide, glipizide, tolbutamide, and tolazamide, and therapeutically equivalent salts and derivatives thereof, and are preferably present in the compositions in concentrations from about 0.1% to 5% by weight.
  • Particular formulations include those suitable for topical application, for injection, and for combination in an ocular insert.
  • Methods according to the present invention comprise administering such compositions directly to the eye in an amount effective to lower the intraocular pressure.
  • Suitable administration methods include topical application, injection, and timed release using an ocular insert or equivalent formulation.
  • the methods and compositions of the present invention are particularly useful for the treatment of glaucoma, and overcome many of the limitations of prior glaucoma treatment methods and compositions.
  • the methods and compositions of the present invention are intended for treatment of glaucoma and other conditions which manifest elevated intraocular pressure in the eye of a patient, particularly human patients, but including other mammalian hosts.
  • Glaucoma is a term which embraces a group of ocular diseases characterized by elevated intraocular pressure levels which can damage the eye. Elevated intraocular pressures often exceed 20 mm/Hg and it is desirable that such elevated pressures be lowered to below 18 mm/Hg. In the case of low-tension glaucoma, it is desirable that the intraocular pressure be lowered below that exhibited by the patient prior to treatment.
  • Glaucoma diseases are well- described in the medical literature. See, e.g., Leibowitz et al. (1980) Suirv. Ophthamol . 24 (Suppl.):366-400 and Leske
  • Intraocular pressure can be measured by conventional tonometry techniques.
  • a particularly convenient method for measuring intraocular pressure is the use of the Tono-Pen as described in Minckler et al. (1987) Am . J. Ophthamol . 104:168-173.
  • Quinine compounds useful for the present invention include quinine (6'-methoxycinchonan-9-ol) , quinidine (3-quinine, an enantio eric form of quinine) , and therapeutically equivalent salts and derivatives thereof.
  • quinine and quinidine particularly useful salts and derivatives include quinine sulfate, quinine acid sulfate, quinine bisulfate, quinine urea hydrochloride, quinine carbonate, quinine ethyl carbonate, quinine gluconate, quinine hydroiodide, quinine hydrobromide, quinine hydrochloride, quinidine sulfate, quinidine gluconate, and quinidine polygalacturonate.
  • Quinine and quinidine are well-known drugs, amply described in the patent and medical literature, and biologically equivalent forms of both quinine and quinidine are well-known.
  • ATP-sensitive K + channel inhibiting compounds useful for the treatment of elevated intraocular pressure conditions include sulfonylureas, such as glybenclamide, glipizide, tolbutamide, and tolazamide (each of these compounds is described in the Merck Index, 10th Edition, with suitable source information provided) , and therapeutically equivalent salts and derivatives thereof.
  • Therapeutically equivalent salts and derivatives are those salts and derivatives of the parent compounds which retain biological activity, i.e.
  • the ATP-sensitive K + channel is one of the approximately 15 K + channels that have been identified.
  • the ATP-sensitive K + channel is regulated by intracellular ATP such that it is spontaneously active in the absence of ATP and closed by increasing ATP concentration in the cytoplas ic side of the membrane.
  • the ATP-sensitive K + channel is not activated by intraocular Ca +2 , and gating of the channel is independent of membrane potential.
  • the channel is selective for K + , and it is selectively inhibited by sulfonylurea compounds, such as glybenclamide, glipizide, tolbutamide, and tolazamide, and the like. It is expected that other selective ATP-sensitive K + channel inhibitors will be identified in the future and that they will be useful in the methods of the present invention.
  • ATP-sensitive K + channels have been identified in cardiac cells, skeletal and smooth muscle, neurons and pancreatic ⁇ - cells. It is very likely that ATP-sensitive K + channels are found in many cells, and the data present in the Experimental section hereinafter indicate existence of such a channel in the eye.
  • a decrease in intraocular pressure occurs when the eye is treated with selective inhibitors of the ATP-sensitive K + channel and an increase in intraocular pressure occurs when the eye is treated with a K + channel opener.
  • such quinine and ATP-sensitive K + channel inhibiting compounds will be incorporated into compositions suitable for direct administration to a patient's eye.
  • direct administration it is meant that the compositions will be applied topically, or by injection or instillation, into the eye.
  • Such direct administration does not include systemic forms of administration, such as oral or parenteral administration, e.g., intramuscular, subcutaneous, or intraperitoneal injection.
  • Direct administration of the compositions is intended to introduce the compounds directly into the eye so that they will be transported into the anterior chamber where the compounds will be effective to lower intraocular pressure, most likely by enhancing the transport or release of intraocular fluid from the anterior chamber or by decreasing fluid production.
  • the active compounds will be administered to the eye in amounts and over a schedule effective to lower the intraocular pressure of the eye, particularly when the intraocular was previously elevated, i.e., above about 20 mm/Hg, usually above 18 mm/Hg, or when damage to the optic nerve is noted.
  • the amount of the quinine or ATP-sensitive K + channel inhibiting compound required for such lowering will depend on a number of factors, including degree of initial pressure elevation, condition of the patient, activity of the particular compound which is being administered, and the like, with exemplary amounts typically being in the range from about 50 ⁇ g to 5 mg per dose (i.e., single application of the composition) , usually being from 250 ⁇ g to 1 mg per dose.
  • compositions having the quinine compound present in a suitable ophthalmically acceptable carrier at a concentration in the range from about 0.1 weight percent to 5 weight percent. Concentrations above 5 weight percent are potentially toxic and should generally be avoided. Specific formulations will be described in greater detail hereinafter.
  • Suitable controlled release articles for use with the compositions of the present invention include solid ocular inserts available from commercial vendors such as Alza Corporation, Palo Alto, California (sold under the Ocusert® trade name) and from Oculex Corporation, Palo Alto, California.
  • controlled-release formulations may be based on polymeric carriers, including both water-soluble polymers and porous polymers having desirable controlled-release characteristics.
  • Particularly suitable polymeric carriers include various cellulose derivatives, such as methylcellulose, sodium carboxymethylcellulose, hydroxyethylcellulose, and the like.
  • Suitable porous polymeric carriers can be formed as polymers and copolymers of acrylic acid, polyacrylic acids, ethylacrylates, methyl ethacrylates, polyacrylamides, and the like.
  • Certain natural biopoly ers may also find use, such as gelatins, alginates, pectins, agars, starches, and the like.
  • a wide variety of controlled-release carriers are known in the art and available for use with the present invention.
  • Topical compositions for delivering the quinine or ATP-sensitive K + channel inhibiting compounds of the present invention will typically comprise the quinine compound present in a suitable ophthalmically acceptable carrier, including both organic and inorganic carriers.
  • suitable ophthalmically acceptable carriers include water, buffered aqueous solutions, isotonic mixtures of water and water-immiscible solvents, such as alkanols, arylalkanols, vegetable oils, polyalkalene glycols, petroleum-based jellies, ethyl cellulose, ethyl oleate, carboxymethylcelluloses, polyvinylpyrrolidones, isopropyl yristates, and the like.
  • Suitable buffers include sodium chloride, sodium borate, sodium acetate, gluconates, and the like. Phosphate buffers are not suitable because of the low solubility of quinine in the presence of phosphate ions.
  • the formulations of the present invention may also contain ophthalmically acceptable auxiliary components, such as emulsifiers, preservatives, wetting agents, thixotropic agents (e.g., polyethylene glycols, antimicrobials, chelating agents, and the like.
  • auxiliary components such as emulsifiers, preservatives, wetting agents, thixotropic agents (e.g., polyethylene glycols, antimicrobials, chelating agents, and the like.
  • antimicrobial agents include quaternary ammonium compounds, benzalkonium chloride, phenylmercuric salts, thi erosal, methyl paraben, propyl paraben, benzyl alcohol, phenylethanol, sorbitan, monolaurate, triethanolamine oleate, polyoxyethylene sorbitan monopal itylate, dioctyl sodium sulfosuccinate, monothioglycerol, and the like.
  • Ethylenediamine tetracetic acid (EDTA) is a suitable chelating agent.
  • compositions of this invention are exemplary of the compositions of this invention. These formulations are illustrative only and are not intended to limit the scope of this invention and should not be so construed.
  • a sterile solution for topically treating glaucoma or reducing intraocular pressure and which is well tolerated by the eye is prepared as follows: Component Amount Quinine 100 ⁇ g to 20 mg
  • a sterile solution for topically treating glaucoma or reducing intraocular pressure is prepared as described in Formula 1 except that quinidine is used in place of quinine.
  • An injectable solution for use in treating glaucoma or reducing intraocular pressure is prepared as follows:
  • FORMULA 4 A sterile injectable solution for treating glaucoma or decreasing intraocular pressure is prepared as described in Formula 3 except that quinidine is used in place of quinine.
  • FORMULA 5 A sterile solution for topically treating glaucoma or reducing intraocular pressure and which is well tolerated by the eye is prepared as follows: Component Amount Glybenclamide 100 ⁇ g to 20 mg
  • An injectable solution for use in treating glaucoma or reducing intraocular pressure is prepared as follows: Component Amount
  • Formulations of inhibitors of ATP-sensitive K + channels were tested for their ability to decrease intraocular pressure in normal rabbits.
  • Diazoxide a K + channel opener, was tested for its ability to raise intraocular pressure in normal rabbits.
  • Formulations were prepare in NaCl/borate buffer (0.8 mg NaCl, 1.0 mg boric acid, pH 7.2, water to 1 ml) and tested as follows: Seventy New Zealand white rabbits were divided into seven groups; 25 were treated with vehicle; 20 were treated with timolal; 10 were treated with glybenclamide; 5 with tolazamide; 10 with tolbutamide; 5 with chlorpropamide, and 5 with diazoxide.
  • intraocular pressure is at least in part dependent on the ratio of intracellular to extracellular potassium.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Des composés à base de quinine sont incorporés à des excipients acceptables pour un usage ophtalmique en vue d'une administration à l'÷il destinée à abaisser la pression intra-oculaire. Ces formulations conviennent en particulier pour traiter le glaucome ou d'autres troubles liés à l'élévation de la pression intra-oculaire.
PCT/US1994/006278 1993-06-08 1994-06-03 Procedes et comositions d'abaissement de la pression intra-oculaire WO1994028900A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU70991/94A AU7099194A (en) 1993-06-08 1994-06-03 Methods and compositions for lowering intraocular pressure
EP94920077A EP0724443A4 (fr) 1993-06-08 1994-06-03 Procedes et comositions d'abaissement de la pression intra-oculaire
JP7501977A JPH08511024A (ja) 1993-06-08 1994-06-03 眼内圧を低下させる方法および組成物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US7380293A 1993-06-08 1993-06-08
US08/073,802 1993-06-08
US08/096,799 US5629345A (en) 1993-07-23 1993-07-23 Methods and compositions for ATP-sensitive K+ channel inhibition for lowering intraocular pressure
US08/096,799 1993-07-23

Publications (1)

Publication Number Publication Date
WO1994028900A1 true WO1994028900A1 (fr) 1994-12-22

Family

ID=26754897

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/006278 WO1994028900A1 (fr) 1993-06-08 1994-06-03 Procedes et comositions d'abaissement de la pression intra-oculaire

Country Status (5)

Country Link
EP (1) EP0724443A4 (fr)
JP (1) JPH08511024A (fr)
AU (1) AU7099194A (fr)
CA (1) CA2164733A1 (fr)
WO (1) WO1994028900A1 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996033719A1 (fr) * 1995-04-28 1996-10-31 Allergan Technique visant a reduire la pression intra-oculaire dans l'oeil d'un mammifere par l'administration d'agents de blocage du canal potassium
EP0955045A1 (fr) * 1996-08-02 1999-11-10 Senju Pharmaceutical Co., Ltd. Medicaments de lutte contre certaines anomalies de la circulation oculaire
US6545036B2 (en) 2000-01-18 2003-04-08 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
US6548535B2 (en) 2000-01-18 2003-04-15 Merck & Co., Inc. Method for treating ocular hypertension
WO2004043932A1 (fr) 2002-11-08 2004-05-27 Merck & Co., Inc. Compositions ophtalmiques pour le traitement de l'hypertension oculaire
US7294646B2 (en) 2002-06-17 2007-11-13 Merck & Co. Inc. Maxi-k channel blockers, methods of use and process for making the same
US7410992B2 (en) 2003-09-04 2008-08-12 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US7414067B2 (en) 2003-03-27 2008-08-19 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US7494983B2 (en) 2003-09-04 2009-02-24 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US7528163B2 (en) 2002-11-08 2009-05-05 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US7563816B2 (en) 2004-07-20 2009-07-21 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US7576122B2 (en) 2003-09-02 2009-08-18 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4895807A (en) * 1986-12-31 1990-01-23 Cherksey Bruce D Membrane channel protein and related therapeutic compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558728B1 (fr) * 1984-01-26 1986-06-06 Sanofi Sa Composition pharmaceutique antipaludeenne a base de quinine, quinidine et cinchonine
FR2568473B1 (fr) * 1984-08-03 1987-05-15 Vaillant Defresne Laboratoire Nouvelle composition a base de formiate de quinine
CA2044853C (fr) * 1990-07-19 2004-11-09 Susan A. Greenfield Methode de traitement de la maladie de parkinson faisant appel a un inhibiteur des vannes a potassium sensible a l'atp
CA2044855A1 (fr) * 1990-07-20 1992-01-21 Kerry P. S. J. Murphy Methode de traitement des agressions contre les neurones susceptibles a la degenerescence parkinsonienne au moyen d'un inhibiteur des vannes a potassium sensibles a l'atp
EP0668864A1 (fr) * 1992-07-17 1995-08-30 Merck & Co. Inc. Biphenylmethylimidazopyridines substituees

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4895807A (en) * 1986-12-31 1990-01-23 Cherksey Bruce D Membrane channel protein and related therapeutic compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0724443A4 *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996033719A1 (fr) * 1995-04-28 1996-10-31 Allergan Technique visant a reduire la pression intra-oculaire dans l'oeil d'un mammifere par l'administration d'agents de blocage du canal potassium
US5573758A (en) * 1995-04-28 1996-11-12 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
EP1243270A1 (fr) * 1995-04-28 2002-09-25 Allergan Sales, Inc. Technique visant a réduire la pression intra-oculaire dans l'oeil d'un mammifère par l'administration d'agents de blocage du canal potassium
EP0955045A1 (fr) * 1996-08-02 1999-11-10 Senju Pharmaceutical Co., Ltd. Medicaments de lutte contre certaines anomalies de la circulation oculaire
EP0955045A4 (fr) * 1996-08-02 2000-11-15 Senju Pharma Co Medicaments de lutte contre certaines anomalies de la circulation oculaire
US6914070B2 (en) 2000-01-18 2005-07-05 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US6548535B2 (en) 2000-01-18 2003-04-15 Merck & Co., Inc. Method for treating ocular hypertension
US6545036B2 (en) 2000-01-18 2003-04-08 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
US6924306B2 (en) 2000-01-18 2005-08-02 Merck & Co. Inc. Method for treating ocular hypertension
US7294646B2 (en) 2002-06-17 2007-11-13 Merck & Co. Inc. Maxi-k channel blockers, methods of use and process for making the same
US7528163B2 (en) 2002-11-08 2009-05-05 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US7196082B2 (en) 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
WO2004043932A1 (fr) 2002-11-08 2004-05-27 Merck & Co., Inc. Compositions ophtalmiques pour le traitement de l'hypertension oculaire
US7547720B2 (en) 2002-11-08 2009-06-16 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US7414067B2 (en) 2003-03-27 2008-08-19 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US7576122B2 (en) 2003-09-02 2009-08-18 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US7410992B2 (en) 2003-09-04 2008-08-12 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US7494983B2 (en) 2003-09-04 2009-02-24 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US7563816B2 (en) 2004-07-20 2009-07-21 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension

Also Published As

Publication number Publication date
JPH08511024A (ja) 1996-11-19
AU7099194A (en) 1995-01-03
EP0724443A1 (fr) 1996-08-07
CA2164733A1 (fr) 1994-12-22
EP0724443A4 (fr) 1997-09-10

Similar Documents

Publication Publication Date Title
Lee et al. Effect of prostaglandin F2 alpha on aqueous humor dynamics of rabbit, cat, and monkey.
KR100452715B1 (ko) 녹내장및안구국소빈혈을치료하기위한특정이소퀴놀린술포닐화합물의용도
CA1332811C (fr) Traitement de l'hypertension oculaire par des bloqueurs des canaux calciques de type i
EP0365662B1 (fr) Compositions antiglaucomateuses contenant des combinaisons d'agonistes alpha-2 et de bloqueurs beta
EP0799615B1 (fr) Gouttes de collyre aux liposomes
US6291498B1 (en) Method for optimizing pupil size using alpha antagonist
US6515006B2 (en) Ophthalmic formulation which modulates dilation
CA2013167A1 (fr) Derives d'isoquinoline pour le traitement du glaucome ou de l'hypertension oculaire
JPH11504330A (ja) カリウムチャンネル遮断剤の投与により、哺乳動物の眼圧を降下する方法
SK280492B6 (sk) Očný prípravok so zníženou viskozitou
US5021410A (en) Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
EP1568382B1 (fr) Medicament contre le glaucome comprenant un inhibiteur de la rho-kinase et un betabloquant
Kyyrönen et al. Improved ocular: systemic absorption ratio of timolol by viscous vehicle and phenylephrine.
EP0724443A1 (fr) Procedes et comositions d'abaissement de la pression intra-oculaire
JP4482726B2 (ja) Ｒｈｏキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤
JP2824863B2 (ja) α▲下１▼―ブロッカー点眼剤
WO1989010757A1 (fr) Nouvelle preparation ophtalmique pour le traitement de glaucomes
EP0338507A2 (fr) Utilisation du mabutérol et de dérivés semblables pour normaliser la tension intra-oculaire
AU680539B2 (en) Use of ergoline derivatives for the treatment of glaucoma
US5965620A (en) Methods and compositions for ATP-sensitive K+ channel inhibition for lowering intraocular pressure
US5079253A (en) Composition for the topical treatment of glaucoma or ocular hypertension
US5629345A (en) Methods and compositions for ATP-sensitive K+ channel inhibition for lowering intraocular pressure
EP1410808A1 (fr) Agents de protection du nerf optique contenant un bloqueur de recepteur alpha 1 en tant qu'ingredient actif
CZ294314B6 (cs) Topické oftalmické léčivo
EP0608604A1 (fr) Ajmaline pour réduire de la pression intraoculaire élevée

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KG KP KR KZ LK LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2164733

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1994920077

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1994920077

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994920077

Country of ref document: EP